Semaglutide, a long-acting GLP-1R agonist similar to liraglutide but with more pronounced weight loss effects, showed an even higher percentage of NASH resolution (59%, 0.4 mg dose) versus placebo (17%) in a 72 week double-blinded phase 2 trial with biopsy-confirmed NASH and liver fibrosis of stages F1–F3.8 This evidence concerns the gene GLP1R and Hepatic fibrosis.